Key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4+ T cell dysfunction in tumor-bearing mice

Journal of Immunology

Volumn 190, Issue 2, 2013, Pages 812-820

  Narita, Yoshinori ^a   Kitamura, Hidemitsu ^a   Wakita, Daiko ^a   Sumida, Kentaro ^a   Masuko, Kazutaka ^a   Terada, Satoshi ^a   Nakano, Kiichiroh ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGINASE 1; GLYCOPROTEIN P 15095; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARGINASE 1 GENE; ARTICLE; CANCER INFILTRATION; CANCER INHIBITION; CANCER STAGING; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; FEMALE; FIBROSARCOMA; GENE EXPRESSION REGULATION; IMMUNE DYSREGULATION; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GENE; UPREGULATION;

ANIMALS; ARGINASE; ARGININE; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84872199075     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103797     Document Type: Article

References (54)

1. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
2. Gabrilovich, D. 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4: 941-952.
3. Jarnicki, A. G., J. Lysaght, S. Todryk, and K. H. Mills. 2006. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 177: 896-904.
4. von Boehmer, H. 2005. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6: 338-344.
5. Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl. 2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886.
6. Yamaguchi, T., and S. Sakaguchi. 2006. Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol. 16: 115-123.
7. Nagaraj, S., K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, D. L. Herber, J. Schneck, and D. I. Gabrilovich. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13: 828-835.
8. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5: 641-654.
9. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
10. Mellman, I., and R. M. Steinman. 2001. Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-258.
11. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. Nature 449: 419-426.
12. Tacken, P. J., I. J. de Vries, R. Torensma, and C. G. Figdor. 2007. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7: 790-802.
13. Munn, D. H., and A. L. Mellor. 2007. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117: 1147-1154.
14. Marigo, I., L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte. 2008. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222: 162-179.
15. Hirano, T. 1998. Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. 16: 249-284.
16. Kitamura, H., H. Kamon, S. Sawa, S. J. Park, N. Katunuma, K. Ishihara, M. Murakami, and T. Hirano. 2005. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 23: 491-502.
17. Park, S. J., T. Nakagawa, H. Kitamura, T. Atsumi, H. Kamon, S. Sawa, D. Kamimura, N. Ueda, Y. Iwakura, K. Ishihara, et al. 2004. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173: 3844-3854.
18. Yeh, H. H., W. W. Lai, H. H. Chen, H. S. Liu, and W. C. Su. 2006. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25: 4300-4309.
19. Kishimoto, T. 2005. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu. Rev. Immunol. 23: 1-21.
20. Dankbar, B., T. Padró, R. Leo, B. Feldmann, M. Kropff, R. M. Mesters, H. Serve, W. E. Berdel, and J. Kienast. 2000. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636.
21. Adachi, Y., C. Aoki, N. Yoshio-Hoshino, K. Takayama, D. T. Curiel, and N. Nishimoto. 2006. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int. J. Cancer 119: 1303-1311.
22. Wei, L. H., M. L. Kuo, C. A. Chen, C. H. Chou, K. B. Lai, C. N. Lee, and C. Y. Hsieh. 2003. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22: 1517-1527.
23. Alberti, L., M. C. Thomachot, T. Bachelot, C. Menetrier-Caux, I. Puisieux, and J. Y. Blay. 2004. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int. J. Cancer 111: 653-661.
24. Chamoto, K., D. Wakita, T. Ohkuri, Y. Uchinami, K. Matsushima, H. Kitamura, and T. Nishimura. 2010. 3-Methylcholanthrene-induced transforming growth factor-beta-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy. Cancer Sci. 101: 855-861.
25. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
26. Corraliza, I. M., M. L. Campo, G. Soler, and M. Modolell. 1994. Determination of arginase activity in macrophages: a micromethod. J. Immunol. Methods 174: 231-235.
27. Trikha, M., R. Corringham, B. Klein, and J. F. Rossi. 2003. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9: 4653-4665.
28. Nishimoto, N., M. Sasai, Y. Shima, M. Nakagawa, T. Matsumoto, T. Shirai, T. Kishimoto, and K. Yoshizaki. 2000. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 56-61.
29. Nishimoto, N., K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, J. Hashimoto, J. Azuma, and T. Kishimoto. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50: 1761-1769.
30. Yokota, S., T. Imagawa, M. Mori, T. Miyamae, Y. Aihara, S. Takei, N. Iwata, H. Umebayashi, T. Murata, M. Miyoshi, et al. 2008. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371: 998-1006.
31. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
32. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
33. Ridge, J. P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474-478.
34. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
35. Grakoui, A., N. H. Shoukry, D. J. Woollard, J. H. Han, H. L. Hanson, J. Ghrayeb, K. K. Murthy, C. M. Rice, and C. M. Walker. 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science 302: 659-662.
36. Hunder, N. N., H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, and C. Yee. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703.
37. Nishimura, T., K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, and A. Ohta. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190: 617-627.
38. Chamoto, K., D. Wakita, Y. Narita, Y. Zhang, D. Noguchi, H. Ohnishi, T. Iguchi, T. Sakai, H. Ikeda, and T. Nishimura. 2006. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res. 66: 1809-1817.
39. Takeshima, T., K. Chamoto, D. Wakita, T. Ohkuri, Y. Togashi, H. Shirato, H. Kitamura, and T. Nishimura. 2010. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 70: 2697-2706.
40. + T cells from patients with GI malignancy. Cancer Immunol. Immunother. 60: 1269-1279.
41. Chung, Y. C., and Y. F. Chang. 2003. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J. Surg. Oncol. 83: 222-226.
42. De Vita, F., M. Orditura, G. Galizia, C. Romano, S. Infusino, A. Auriemma, E. Lieto, and G. Catalano. 1999. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 86: 1936-1943.
43. Karin, M., and F. R. Greten. 2005. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5: 749-759.
44. Yu, H., M. Kortylewski, and D. Pardoll. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7: 41-51.
45. Rodriguez, P. C., D. G. Quiceno, and A. C. Ochoa. 2007. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109: 1568-1573.
46. Schmidt, L. M., M. G. Belvisi, K. A. Bode, J. Bauer, C. Schmidt, M. T. Suchy, D. Tsikas, J. Scheuerer, F. Lasitschka, H. J. Gröne, and A. H. Dalpke. 2011. Bronchial epithelial cell-derived prostaglandin E2 dampens the reactivity of dendritic cells. J. Immunol. 186: 2095-2105.
47. Gannon, P. O., J. Godin-Ethier, M. Hassler, N. Delvoye, M. Aversa, A. O. Poisson, B. Péant, M. Alam Fahmy, F. Saad, R. Lapointe, and A. M. Mes-Masson. 2010. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS ONE 5: e12107.
48. Corzo, C. A., T. Condamine, L. Lu, M. J. Cotter, J. I. Youn, P. Y. Cheng, H. I. Cho, E. Celis, D. G. Quiceno, T. Padhya, et al. 2010. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207: 2439-2453.
49. Sumida, K., D. Wakita, Y. Narita, K. Masuko, S. Terada, K. Watanabe, T. Satoh, H. Kitamura, and T. Nishimura. 2012. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur. J. Immunol. 42: 2060-2072.
50. Koh, E., T. Iizasa, H. Yamaji, Y. Sekine, K. Hiroshima, I. Yoshino, and T. Fujisawa. 2012. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int. J. Surg. Pathol. 20: 233-239.
51. Belluco, C., D. Nitti, M. Frantz, P. Toppan, D. Basso, M. Plebani, M. Lise, and J. M. Jessup. 2000. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann. Surg. Oncol. 7: 133-138.
52. Negrier, S., D. Perol, C. Menetrier-Caux, B. Escudier, M. Pallardy, A. Ravaud, J. Y. Douillard, C. Chevreau, C. Lasset, and J. Y. Blay; Groupe Francais d'Immunotherapie. 2004. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. [Published erratum appears in 2004 J. Clin. Oncol. 22: 4656.] J. Clin. Oncol. 22: 2371-2378.
53. Alcover, J., X. Filella, P. Luqué, R. Molina, L. Izquierdo, J. M. Augé, and A. Alcaraz. 2010. Prognostic value of IL-6 in localized prostatic cancer. Anticancer Res. 30: 4369-4372.
54. Garcia-Tuñón, I., M. Ricote, A. Ruiz, B. Fraile, R. Paniagua, and M. Royuela. 2005. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 47: 82-89.